Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin

Nephron - Clinical Practice

Volumn 96, Issue 3, 2004, Pages

  Swanson, Steven J ^a   Ferbas, John ^a   Mayeux, Patrick ^b   Casadevall, Nicole ^c  

^a AMGEN INC   (United States)

^b Hôpital Cochin ^*  (France)

^c HÔTEL DIEU   (France)

Author keywords

Anemia; BIAcore assay; Biosensor; Enzyme linked immunosorbent assay; Immunoassay; Isotype; Neutralizing antibodies; Pure red cell aplasia; Radioimmune precipitation assay

Indexed keywords

ERYTHROPOIETIN ANTIBODY; HORMONE ANTIBODY; IMMUNOGLOBULIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY DETECTION; ARTICLE; BIOSENSOR; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE APLASIA; EVALUATION; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTIBODIES; ANTIBODY SPECIFICITY; BIOLOGICAL ASSAY; BIOSENSING TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; IMMUNOASSAY; RADIOIMMUNOPRECIPITATION ASSAY; RED-CELL APLASIA, PURE;

EID: 1842611598     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076746     Document Type: Article

References (12)

1. Montagnac R, Boffa GA, Schilinger F, Guillaumie J: Sensibilisation à l'erythropoétine humaine recominante chez une hémodialysée. Presse Méd 1992;21:84-85.
2. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M: A case of anti-erythropoietin antibodies following recombinant human erythropoietin treatment; in Bauer C, Koch KM, Scigalla P, Wieczorek L (eds): Erythropoietin: Molecular Physiology and Clinical Application. New York, Marcel Dekker, 1993, pp 266-275.
3. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P: Brief report: Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-633.
4. Peces R, De La Torre M, Alcazar R, Urra J: Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335:523-524.
5. Prabhakar SS, Muhlfelder T: Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47:331-335.
6. Casadevell N: Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 2002;17(suppl 5):42-47.
7. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, MartinDupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeaux P: Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-475.
8. Gershon SK, Luksenburg H, Cote TR, Braun MM: Pure red cell aplasia and recombinant erythropoietin. Letter to the Editor. N Engl J Med 2002;346:1584-1585.
9. Swanson SJ, Mytych D, Ferbas J: Use of biosensors to monitor the immune response. Dev Biol 2002:109:71-78.
10. Porter S: Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11.
11. Koren E, Zuckerman LA, Mire-Sluis AR: Immune response to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002;3:349-360.
12. Agence Francaise de Securite des Produits de Sante. Eprex®: Contre-indication de la voie SC chez les insuffiscants rénaux chronique. www.afssaps.sante.fr accessed 16 December 2002.